TABLE 1.
Patient and tumor characteristics, National Cancer Data Base, 2004–2016
| All patients (N = 94,487) | Locoregional advanced (N = 12,325) | CAM (N = 122) | M1 (N = 82,040) | p | |
|---|---|---|---|---|---|
| Age – median (IQR) | 61 (51–71) | 55 (46–64) | 57 (48–63) | 62 (52–73) | < 0.001 |
| Gender | < 0.001 | ||||
| Female | 93,224 (98.7%) | 12,223 (99.2%) | 121 (99.2%) | 80,880 (98.6%) | |
| Race/ethnicity | < 0.001 | ||||
| Non-Hispanic black | 15,204 (16.1%) | 2,051 (16.6%) | 24 (19.7%) | 13,129 (16%) | |
| Non-Hispanic white | 65,473 (69.3%) | 8,170 (66.3%) | 86 (70.5%) | 57,217 (69.7%) | |
| Hispanic | 5,259 (5.6%) | 981 (8%) | 8 (6.6%) | 4,270 (5.2%) | |
| Other | 3,058 (3.2%) | 483 (3.9%) | 1 (0.8%) | 2,574 (3.1%) | |
| Charlson/Deyo comorbidity score | < 0.001 | ||||
| 0 | 7,6412 (80.9%) | 10,568 (85.7%) | 104 (85.2%) | 65,740 (80.1%) | |
| 1 | 13,135 (13.9%) | 1,441 (11.7%) | 14 (11.5%) | 11,680 (14.2%) | |
| >2 | 4,940 (5.2%) | 316 (2.6%) | 4 (3.3%) | 4,620 (5.6%) | |
| Tumor size (cm) – median (IQR) | 4 (2.4–6) | 3.7 (2.4–6) | 3.95 (2.5–6.05) | 4 (2.4–6) | < 0.001 |
| Histology | < 0.001 | ||||
| Ductal | 60,884 (64.4%) | 9,333 (75.7%) | 98 (80.3%) | 51,453 (62.7%) | |
| Lobular | 15,257 (16.1%) | 2,051 (16.6%) | 10 (8.2%) | 13,196 (16.1%) | |
| Other | 18,346 (19.4%) | 941 (7.6%) | 14 (11.5%) | 17,391 (21.2%) | |
| Grade | < 0.001 | ||||
| 1 | 5,299 (5.6%) | 478 (3.9%) | 0 (0%) | 4,821 (5.9%) | |
| 2 | 28,528 (30.2%) | 3,465 (28.1%) | 32 (26.2%) | 25,031 (30.5%) | |
| 3 | 36,998 (39.2%) | 7,273 (59%) | 77 (63.1%) | 29,648 (36.1%) | |
| ER status | < 0.001 | ||||
| ER+ | 63,073 (66.8%) | 7,386 (59.9%) | 84 (68.9%) | 55,603 (67.8%) | |
| ER− | 22,972 (24.3%) | 4,756 (38.6%) | 37 (30.3%) | 18,179 (22.2%) | |
| PR status | < 0.001 | ||||
| PR+ | 50,026 (52.9%) | 5,881 (47.7%) | 56 (45.9%) | 44,089 (53.7%) | |
| PR− | 34,893 (36.9%) | 6,223 (50.5%) | 64 (52.5%) | 28,606 (34.9%) | |
| HER2 status * | < 0.001 | ||||
| HER2+ | 13,041 (22.2%) | 2,121 (26.5%) | 23 (28%) | 10,897 (21.5%) | |
| HER2− | 38,084 (64.9%) | 5,486 (68.6%) | 56 (68.3%) | 32,542 (64.3%) | |
| Tumor subtype * | < 0.001 | ||||
| HER2+ | 13,041 (22.2%) | 2,121 (26.5%) | 23 (28%) | 10,897 (21.5%) | |
| HR+/HER2− | 30,093 (51.3%) | 3,577 (44.7%) | 43 (52.4%) | 26,473 (52.3%) | |
| Triple-negative | 7,767 (13.2%) | 1,902 (23.8%) | 13 (15.9%) | 5,852 (11.6%) | |
| Clinical T-stage | < 0.001 | ||||
| cT0/IS | 1,611 (1.7%) | 102 (0.8%) | 2 (1.6%) | 1,507 (1.8%) | |
| cT1 | 11,061 (11.7%) | 1,657 (13.4%) | 15 (12.3%) | 9,389 (11.4%) | |
| cT2 | 24,223 (25.6%) | 4,637 (37.6%) | 34 (27.9%) | 19,552 (23.8%) | |
| cT3 | 12,966 (13.7%) | 2,873 (23.3%) | 11 (9%) | 10,082 (12.3%) | |
| cT4 | 27,924 (29.6%) | 2,757 (22.4%) | 50 (41%) | 25,117 (30.6%) | |
| cTX | 15,957 (16.9%) | 290 (2.4%) | 9 (7.4%) | 15,658 (19.1%) | |
| Clinical N-stage | ‡ | ||||
| cN0 | 18,672 (19.8%) | 0 (0%) | 29 (23.8%) | 18,643 (22.7%) | |
| cN1 | 28,342 (30%) | 0 (0%) | 40 (32.8%) | 28,302 (34.5%) | |
| cN2 | 10,012 (10.6%) | 825 (6.7%) | 20 (16.4%) | 9,167 (11.2%) | |
| cN3 | 20,088 (21.3%) | 11,500 (93.3%) | 28 (23%) | 8,560 (10.4%) | |
| cNX | 16,641 (17.6%) | 0 (0%) | 5 (4.1%) | 16,636 (20.3%) | |
| Pathologic T-stage | < 0.001 | ||||
| pT0/IS | 2,621 (2.8%) | 1,622 (13.2%) | 13 (10.7%) | 986 (1.2%) | |
| pT1 | 6,170 (6.5%) | 2,467 (20%) | 28 (23%) | 3,675 (4.5%) | |
| pT2 | 8,863 (9.4%) | 2,948 (23.9%) | 30 (24.6%) | 5,885 (7.2%) | |
| pT3 | 4,484 (4.7%) | 1,599 (13%) | 14 (11.5%) | 2,871 (3.5%) | |
| pT4 | 5,497 (5.8%) | 886 (7.2%) | 19 (15.6%) | 4,592 (5.6%) | |
| pTX | 4,7181 (49.9%) | 2,506 (20.3%) | 15 (12.3%) | 44,660 (54.4%) | |
| Pathologic N-stage | < 0.001 | ||||
| pN0 | 6,100 (6.5%) | 2,220 (18%) | 37 (30.3%) | 3,843 (4.7%) | |
| pN1 | 6,957 (7.4%) | 1,463 (11.9%) | 22 (18%) | 5,472 (6.7%) | |
| pN2 | 5,017 (5.3%) | 1,302 (10.6%) | 20 (16.4%) | 3,695 (4.5%) | |
| pN3 | 7,659 (8.1%) | 4,714 (38.2%) | 19 (15.6%) | 2,926 (3.6%) | |
| pNX | 48,815 (51.7%) | 2,326 (18.9%) | 18 (14.8%) | 46,471 (56.6%) |
‡
Variable used in study group definition
*
HER2 status and tumor subtype reported for patients diagnosed 2010 and afterData presented as N (%) unless otherwise specified. Percentages may not add up to 100 due to rounding or missing values
IQR interquartile range; ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor 2